The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting the high-risk nature of neurological drug development, GSK has officially terminated its neuroscience collaboration agreement with Alector. The decision follows clinical setbacks for two experimental antibody drug candidates that failed to meet expectations in trials. According to reports, this termination marks the end of a partnership focused on developing treatments for dementia and Alzheimer's disease.
The move represents a significant setback for Alector, which relies on major pharmaceutical partnerships for pipeline funding; the 2021 deal originally included substantial upfront payments and potential milestones. In contrast, peers such as Eli Lilly and Biogen have successfully brought Alzheimer's treatments like 'Kisunla' and 'Leqembi' to market, leaving GSK trailing in this specific therapeutic race per market data.
Shares of GSK stood at $52.52 at close on July 8, 2026, as investors weigh the impact of this withdrawal on the company's long-term R&D strategy. Looking ahead, market participants will monitor broader sector sentiment following upcoming U.S. inflation data, as the current economic calendar shows few immediate catalysts specifically for the pharmaceutical giant.